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Abstract
Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of child-
hood epilepsy syndromes. Distinct de novomutations in the SCN1A gene are responsible
for over 80% of DS cases. While DS is largely resistant to treatment with existing anti-epi-
leptic drugs, promising results have been obtained in clinical trials with human patients
treated with the serotonin agonist fenfluramine as an add-on therapeutic. We developed a
zebrafish model of DS using morpholino antisense oligomers (MOs) targeting scn1Lab, the
zebrafish ortholog of SCN1A. Zebrafish larvae with an antisense knockdown of scn1Lab
(scn1Labmorphants) were characterized by automated behavioral tracking and high-reso-
lution video imaging, in addition to measuring brain activity through local field potential re-
cordings. Our findings reveal that scn1Labmorphants display hyperactivity, convulsive
seizure-like behavior, loss of posture, repetitive jerking and a myoclonic seizure-like pattern.
The occurrence of spontaneous seizures was confirmed by local field potential recordings
of the forebrain, measuring epileptiform discharges. Furthermore, we show that these lar-
vae are remarkably sensitive to hyperthermia, similar to what has been described for
mouse models of DS, as well as for human DS patients. Pharmacological evaluation re-
vealed that sodium valproate and fenfluramine significantly reduce epileptiform discharges
in scn1Labmorphants. Our findings for this zebrafish model of DS are in accordance with
clinical data for human DS patients. To our knowledge, this is the first study demonstrating
effective seizure inhibition of fenfluramine in an animal model of Dravet syndrome.
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Moreover, these results provide a basis for identifying novel analogs with improved activity
and significantly milder or no side effects.
Introduction
Dravet syndrome (DS) is a devastating form of childhood epilepsy that begins with prolonged
seizures in the first year of life. The initial seizures are often febrile, generalized or unilateral,
clonic or tonic–clonic [1]. EEG findings are mainly normal at onset, whereas epileptiform ac-
tivity typically becomes evident in the second or third year or later [2]. Early development is
normal, but signs of cognitive and behavioral comorbidities appear in the second year of life.
Non-febrile seizures become more frequent and include convulsive status absence, myoclonic,
simple and complex partial seizures [1,3,4]. Distinct de novomutations in the alpha subunit of
voltage-gated sodium-channel (VGSC) type 1 gene, SCN1A, are known to be causative of DS,
mutations of which occur in 85% of Dravet patients [5]. VGSCs play an essential role in neuro-
nal excitability by initiating and propagating the rising phase of the action potential; therefore,
it is not surprising that many mutations associated with DS have been identified in SCN1A [6].
DS is one of the most pharmacoresistant epilepsy syndromes [7]. The main challenges are
to reduce seizure frequency as much as possible, to prevent the occurrence of status epilepticus,
and to optimize the development of cognitive functions [7]. Stiripentol is the only compound
that has shown some efficacy in DS patients through two independent randomized placebo-
controlled add-on trials, when combined with valproate and clobazam [8,9]. However, these
agents do not yield complete seizure freedom and may cause adverse side effects [10]. New, ef-
fective antiepileptic drugs (AEDs) with possibly novel mechanisms of action would therefore
significantly improve current treatment options [11,12]. In a recent clinical study, the anticon-
vulsant activity of fenfluramine was tested. Seventy percent of children treated with add-on
fenfluramine were seizure-free for more than 1 year, which is better than any other treatment
option tried for Dravet syndrome to date [13]. Therefore, fenfluramine is proposed as a new
and potent anti-epileptic add-on drug in DS. Fenfluramine is a potent 5-HT (serotonin) releas-
er. Serotonin is able to activate multiple 5-HT receptor subtypes, of which 14 different ones
have been described in humans. Moreover, the N-dealkylated metabolite of fenfluramine, i.e.
norfenfluramine, displays high affinity and activity at the 5-HT2B and 5-HT2C receptor sub-
types [14]. Which 5-HT receptor subtypes are involved in the anti-epileptic effect of fenflur-
amine is presently unknown. 5-HT2C receptor agonists trigger appetite suppression [15].
Conversely, the activation of 5-HT2B receptors is associated with cardiac valve injury [16].
Thus, the current challenge is to determine whether the mechanism underlying fenfluramine’s
anticonvulsant activity is the same or different from the mechanism leading to valvulopathies.
It should be noted, however, that the dose used for treating DS children in clinical studies was
considerably lower than the fenfluramine dose, used in the treatment of obesity that was associ-
ated with cardiac valve injury. To date, however, fenfluramine has not been evaluated in animal
models of DS.
Several mouse DS models, and more recently also a zebrafish DS model, have been de-
scribed that strikingly recapitulate the DS phenotype including age and temperature depen-
dence of spontaneous epileptic seizures and ataxia [17–21], proving the possibility to study the
syndrome in animal models and to potentially use these models to screen for novel therapeu-
tics. Due to a partial genome duplication in teleost fishes, zebrafish express two paralogs of
each member of the VGSC gene family: scn1Laa and scn1Lab, scn5Laa and scn5Lab, and
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scn8aa and scn8ab, which encode Nav1.1La and Nav1.1Lb, Nav1.5La and Nav1.5Lb, Nav1.6a
and Nav1.6b, respectively [22]. Previous phylogenetic and expression pattern analyses have in-
dicated that zebrafish scn1Lab is evolutionarily most closely related to the mammalian SCN1A,
SCN2A, and SCN3A genes [23]. It was shown that scn1Lab displays neuronal expression pat-
tern in both zebrafish embryos (24 hours post-fertilization) and adults [22,23]. The zebrafish
scn1Labmutant, double indemnity (didy), was discovered in an ENU-mutagenesis screen and
has been investigated in two studies. Schoonheim et al. characterized the didy phenotype based
on a defect in sustaining saccades during the optokinetic response [24], whereas Baraban et al.
recently demonstrated that scn1Labmutants exhibit spontaneous seizures [21]. These didymu-
tants were used to identify compounds that rescue the phenotype, such as clemizole, an FDA-
approved drug, that effectively inhibits spontaneous convulsive seizures both at behavioral and
electrographic level [21].
In order to be able to rapidly analyze the potential anti-epileptic activity of fenfluramine, we
developed a zebrafish model for this disorder using morpholino antisense oligomers targeting
scn1Lab, the zebrafish ortholog of SCN1A. Here we describe the pathophysiological and phar-
macological characterization of this zebrafish DS model, which displays abnormal locomotor
behavior, recurrent electrographic discharges and age-dependent hyperthermia sensitivity. Sei-
zure-like locomotor behavior and electrographic discharges in this model are effectively treated
with fenfluramine, thereby providing further evidence for this drug candidate as a potential
therapeutic for DS and demonstrating the utility of this zebrafish DS model for rapidly evaluat-
ing potential new small-molecule therapeutics for DS.
Methods
Zebrafish maintenance and breeding
Adult zebrafish (Danio rerio) stocks of the AB strain (Zebrafish International Resource Center,
Oregon, USA) were maintained at 28.0°C, on a 14/10 hour light/dark cycle under standard
aquaculture conditions. Fertilized eggs were collected via natural spawning. Embryos and lar-
vae were kept on a 14/10 hour light/dark cycle in embryo medium: 1.5 mMHEPES, pH 7.6,
17.4 mM NaCl, 0.21 mM KCl, 0.12 mMMgSO4, and 0.18 mM Ca(NO3)2 in an incubator at
28.0°C. All zebrafish experiments carried out were approved by the Ethics Committee of the
University of Leuven (Ethische Commissie van de KU Leuven, approval number (061/2013)
and by the Belgian Federal Department of Public Health, Food Safety & Environment (Federale
Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmileu, approval
number LA1210199).
Antisense morpholino oligomers (MO) and microinjections
9 ng of a translation blocking MO (ATGMO: 5’-CTGAGCAGCCATATTGACATCCTGC-3’)
was used to achieve partial knockdown of zebrafish scn1Lab. Standard control MO (5'-CCTC
TTACCTCAGTTACAATTTATA) or randomized 25-N MO was used as a negative control
(CTRL MO) (9 ng). All MOs were designed and synthesized by GeneTools LLC (Philomath,
Oregon, USA) and injected into one- to two-cell stage embryos.
Larval locomotor behavior
In order to assess the locomotor behavior of Dravet syndrome morphant model, scn1Labmor-
phants and control larvae were placed in a 96-well plate in 200 μL of embryo medium from 3
to 7 days post fertilization (dpf). Each day the larvae were tracked in an automated tracking
device (ZebraBox apparatus; Viewpoint, Lyon, France) for one hour (30-minute integration
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interval), followed by a 30-minute chamber of habituation under white light, as all recordings
were performed at the same time during daytime period. The total movement was recorded,
then, quantified using ZebraLab software (Viewpoint, Lyon, France) and plotted in “actinteg”
units, which is the sum of all pixel changes detected during the experimental period [25]. Data
were pooled together from three independent experiments with twelve larvae per injection
condition.
Generation of zebrafish larvae with non-inflated swim bladder
Dechorionated 2-dpf control larvae were placed in a 6-well plate filled to the brim with embryo
medium and covered with a glass lid in order to prevent larvae from being exposed to air,
thereby preventing them inflating their swim bladders. At 5 dpf, larvae were tracked in an auto-
mated tracking device as described, using similar conditions that prevented them to fill their
swim bladders with air.
Local field potential recordings
Open-field recordings were obtained from zebrafish larval forebrain at 5 dpf at 24°C [26]. A
glass electrode, connected to a high-impedance amplifier, was filled with artificial cerebrospinal
fluid (124 mMNaCl, 2 mM KCl, 2 mMMgSO4, 2 mM CaCl2, 1.25 mM KH2PO4, 26 mM
NaHCO3 and 10 mM glucose). A larva was then embedded in 2% low-melting-point agarose
(Invitrogen) and the glass electrode (2–7 MΩ) placed into the forebrain of the larva. The re-
cordings were performed in current clamp mode with parameters: low-pass filtered at 1 kHz,
high-pass filtered 0.1 Hz, digital gain 10 and sampling interval 10 μs (MultiClamp 700B ampli-
fier, Digidata 1440A digitizer, both Axon instruments, USA). Single recordings were performed
for ten minutes. Both fenfluramine and sodium valproate were applied 24 hours prior to extra-
cellular recordings. In order to inhibit the spontaneous epileptiform activity of scn1Labmor-
phants, they were incubated with a mixture of 20 μM 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX), and 50 μMDL-2-amino-5-phosphonopentanoic acid (APV), 30 min prior to fore-
brain LFP recordings. Control larvae were exposed to 20 mM pentylenetetrazole (PTZ) to in-
duce epileptiform activity or to a mixture containing 20 mM PTZ, 20 μMCNQX and 50 μM
APV, 30 min prior to midbrain LFP recordings. Spontaneous epileptiform events were taken
into account when the amplitude exceeded three times the background noise. The analysis of
spikes was carried out using Clampfit 10.2 software (Molecular Devices Corporation, USA).
Hyperthermia-induced abnormalities
scn1Labmorphants and control larvae (8 larvae per condition between 3 and 7 dpf) were
placed in 0.2 ml PCR tubes filled with 50 μL embryo medium, exposed to a rapid (ca. 10 s) tem-
perature change from 28°C to 39°C and maintained at 39°C for 10 min in a thermal cycler. Af-
terwards, larvae were transferred to a 6-well plate at 28°C on a 14/10 hour light/dark cycle
under standard aquaculture conditions and observed for 24 hours. In order to evaluate the ef-
fect of fenfluramine and sodium valproate on the outcome, 4-dpf scn1Labmorphants and con-
trol larvae were exposed to the compounds 24 hours prior to heatshock treatment. To quantify
the severity of hyperthermia-induced abnormalities, 24 hours after heatshock, cumulative scor-
ing was used. Normal behavior was scored as 0, decreased touch response and partial loss of
posture as 1, absent touch response and complete loss of posture as 2, and death as 3. To obtain
a cumulative score, the number of larvae was multiplied by the value that corresponded to the
level of severity. Data for hyperthermia-induced abnormalities were pooled together from
three independent experiments.
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Drugs
Carbamazepine (CBZ), topiramate (TPR), stiripentol (STP), pentylenetetrazole (PTZ),
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and DL-2-amino-5-phosphonopentanoic acid
(APV) were purchased from Sigma-Aldrich, sodium valproate (VPA) from Sanofi-Aventis,
clobazam (CLB) from Lipomed AG, Switzerland and fenfluramine (FA) from Peak Interna-
tional Products B.V. Compounds were dissolved in DMSO and diluted in embryo medium to
achieve a final DMSO concentration of 1% w/v, which served as a vehicle control (VHC). In
case of treatment for the hyperthermia-experiment, a final DMSO concentration of 0.1% w/v
was used.
Determination of maximal tolerated concentration (MTC)
Freely swimming 3 dpf scn1Labmorphants and control larvae were incubated in 96-well plate
format with AEDs or VHC at 28°C on a 14/10 hour light/dark cycle under standard aquacul-
ture conditions (medium was replenished after 24 hours of incubation at 4 dpf). Each larva was
individually checked under the microscope for the following signs of acute locomotor im-
pairment and toxicity, such as decreased or absent touch response, loss of posture, body defor-
mation, slow or absent heartbeat, and death after 24 hours (4 dpf) and 48 hours (5 dpf) of
incubation. A larva was considered normal if it could cover a distance twice its body length. A
shorter distance traveled or movement in the same place was scored as a decreased or impaired
touch response. No visible movement upon a touch stimulus was counted as absent response.
Thus, the MTC was defined as the maximum concentration, which did not cause death, dys-
morphology, abnormal heart rate and where not more than two out of twelve larvae exhibited
any sign of locomotor impairment including absent touch response and loss of balance after
24 and 48 hours of incubation. All vehicle-treated (VHC), control larvae displayed no signs
of locomotor impairment or toxicity and had normal heart rates after 24 and 48 hours of
incubation.
Pharmacological evaluation of larval locomotor behavior
Freely swimming 3 dpf scn1Labmorphants and control larvae were pre-incubated in 200 μl of
different concentrations of AEDs (at or below the MTC) or VHC for 24 hours in individual
wells of a 96-well plate at 28°C on a 14/10 hour light/dark cycle under standard aquaculture
conditions. After 24 hours of incubation and 30-minute chamber habituation 4 dpf larvae were
tracked for locomotor behavior for one hour (30 minutes integration interval) under white
light. After tracking, the embryo medium with AEDs was replenished for another 24 hours
(with same concentrations). Same tracking experiments were performed with 5 dpf larvae after
48 hours of incubation. The total locomotor activity was quantified using ZebraLab software
(Viewpoint, Lyon, France) and plotted in “actinteg” units. Data were pooled together from two
(CBZ, CLB, STP, TOP) or three (VPA, FA) independent experiments with twelve larvae per
injection condition.
Video recordings
Individual scn1Labmorphant or control larva was placed into a glass well (inner diameter:
7 mm, depth: 2 mm) filled with embryo medium and filmed for 20 seconds using a Carl Zeiss
Stemi 2000-C stereomicroscope equipped with digital camera (InSight 2Mp, Diagnostic Instru-
ments) run by VisiView software (ID 1216) (Exposure time: 10 msec, time interval: 200 msec).
Each larva was kept at 28°C by the following method: the glass well with the larva was warmed
up by a home-made glass-heating element (connected to a water bath) in which water was
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circulated by a peristaltic pump. Temperature of the embryo medium in the glass well was
measured at each recording with a micro-thermometer probe (Testo AG, Germany).
Imaging
scn1Labmorphants and control larvae were photographed using a Leica MZ10 F stereomicro-
scope equipped with a DFC310 FX digital camera run by Leica Application Suite software (ver-
sion 3.6.0).
Statistical analysis
Statistical analyses were performed using Mann–Whitney test, (larval locomotor behavior),
Student’s two-tailed unpaired t-test or Mann–Whitney–Rank sum test for data that failed the
normality test, as appropriate (local field potential recordings). Outliers of the assessment of
data for pharmacological evaluation of larval locomotor behavior were removed using Iterative
Grubbs’method. Data were then analyzed by one-way ANOVA followed by Dunnett’s multi-
ple comparison test with GraphPad Prism 6.01 software.
Results and Discussion
Characterization of the zebrafish scn1Labmorphant phenotype
Antisense morpholino knockdown. A Dravet syndrome morphant model was generated
by knocking down the zebrafish scn1Lab gene using morpholino antisense oligomer. The MO
targeted the region spanning the 5’UTR and translational start site of scn1LabmRNA (ATG
MO). Ideally, the level of knock down via translation inhibition with ATGMO should be eval-
uated by Western blotting. However, no proper antibody exists currently to determine the anti-
sense effects of ATGMO [21]. Two different antibodies were tested. Unfortunately, none of
them showed specificity against zebrafish Nav1.1Lb (Abcam—Anti-Scn1a antibody (ab24820)
and Biorbyt Anti-SCN1A antibody (orb13681), data not shown).
Morphological description. We performed visual inspection of scn1Labmorphants from
1 dpf to 7 dpf, and observed that between 3 and 7 dpf, larvae failed to inflate their swim blad-
der, were hyperpigmented and displayed slightly curved body axes (data shown at 5 dpf, Fig
1B). Moreover, no signs of necrosis, axis truncation, pericardial edemas or any other dys-
morphologies were observed. This observed phenotype is identical to the already described
findings for the scn1Labmutant [21,24]. Thus, scn1Labmorphants phenocopied the reported
genetic scn1Labmutant, underscoring the specificity of the MO. At all stages studied, control
embryos and larvae displayed normal phenotypes (data shown at 5 dpf, Fig 1A).
Assessment of larval locomotor behavior. An automated video-based behavioral tracking
system (ZebraBox, ViewPoint, France) was used to simultaneously monitor and quantify the
locomotor activity of freely swimming scn1Labmorphant and control larvae individually ar-
rayed in 96-well plate from 3 dpf to 7 dpf. The scn1Labmorphants displayed spontaneously in-
creased total movement as compared to control larvae. The increase of total movement was
initially observed at 3 dpf and became more pronounced at 4 and 5 dpf (p<0.001) (Fig 1C),
thus showing Stage I seizure-like behavior as described previously [27]. In order to characterize
the locomotor behavior of the scn1Labmorphant in more detail, we performed higher-resolu-
tion video recording to capture more subtle larval seizure behaviors not detected by the auto-
mated tracker. scn1Labmorphant larvae displayed not only increased total movement but also
abnormal behavior. Larvae displayed jerking behavior and sudden stiffening and relaxation of
the entire body (S1 and S2 Videos, shown at 5 and 6 dpf). Other phenotypic traits that typified
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the scn1Labmorphant larvae were a non-inflated swim bladder and a bent axis (Fig 1B), as ob-
served before in the scn1Lab/didy mutant [24],
In order to investigate whether the balance defects and/or abnormal behavior were caused by
the swim bladder defect, we generated control larvae (CTRLMO-injected larvae) with non-inflated
Fig 1. Morphology and larval locomotor activity of scn1LabATGmorphants. (A) Dorsal view of a representative 5 dpf CTRL MO-injected larva. (B)
Dorsal view of a representative 5 dpf ATGMO-injected larva. (C) The y-axis depicts the total larval locomotor activity of ATGMO- compared to CTRL MO-
injected larvae over a one-hour tracking experiment (30-minute integration time). Data were pooled from three independent experiments with 12 larvae per
injection condition. Statistical analysis was performed using Mann-Whitney test. Error bars on all graphs represent the standard error of mean (SEM). ***
P 0.001.
doi:10.1371/journal.pone.0125898.g001
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swim bladders (NISB CTRLMO). Under normal circumstances, 2-3-dpf larvae show swim-up be-
havior to inflate the swim bladder at the surface, a spontaneous behavior which occurs almost im-
mediately after hatching [28]. By preventing the larvae to surface, we were able to prevent larvae to
inflate their swim bladders. Interestingly, we observed up to 6 dpf that NISB-control larvae also
showed a slightly bent axis (data shown at 5 dpf, Fig 2A) and altered behavior such as difficulties
Fig 2. Morphology and larval locomotor activity of scn1LabATGmorphants in comparison to control larvae with non-inflated swim bladder. (A)
Dorsal view of a representative 5-dpf CTRL MO-injected larva with non-inflated swim bladder (NISB CTRLMO). (B) The y-axis depicts the total larval
locomotor activity of ATGMO- compared to CTRL MO-injected larvae and CTRLMO-injected larvae win non-inflated swim bladder (NISB CTRLMO) over a
one-hour tracking experiment (30-minute integration time). Data were analyzed from one experiment with 8–12 larvae per injection condition. Statistical
analysis was performed using Dunnett's multiple comparisons test. Error bars on all graphs represent standard error of mean (SEM). * P 0.05, ** P 0.01.
doi:10.1371/journal.pone.0125898.g002
Antisense Knockdown Zebrafish Model of Dravet Syndrome
PLOSONE | DOI:10.1371/journal.pone.0125898 May 12, 2015 8 / 19
in maintaining balance (transient loss of posture) and subtle movements, similar to scn1Labmor-
phants (S3 and S4 Videos, shown at 5 and 6 dpf). These locomotor defects were never observed in
any of the control larvae (with inflated swim bladder) (S5 and S6 Videos, shown at 5 and 6 dpf).
Then, at 5 dpf the total movement of NISB-control larvae was compared to control siblings
with normally inflated swim bladders and scn1Labmorphant larvae, which have morpholino-
induced non-inflated swim bladders. Importantly, we found that the total movement of control
larvae was comparable to NISB-control larvae (p = 0.9333, Fig 2B). Hence, we concluded that
the abnormal hyperactive behavior of the scn1Labmorphants between 3 and 5 dpf is not due
to swim bladder deficiency, but very likely due to abnormal brain activity as confirmed by local
field potential (LFP) measurements (see further). Conversely, the abnormal behavior seen in 6
dpf scn1Labmorphants (shown in S2 Video), as also observed in the control larvae with non-
inflated swim bladders, can be related to the lack of the swim bladders (shown in S3 and S4
Videos). The latter movements, at least in part due to the lack of swim bladders, are not picked
up by the automated tracker (Fig 1C: non-significant difference at 6 and 7 dpf), whereas the hy-
peractivity of the scn1Labmorphants (i.e. not related to the lack of the swim bladders), can eas-
ily be observed between 3 and 5 dpf (Fig 1C and S1 Video).
Local field potential recordings. To confirm that scn1Lab knockdown resulted in abnor-
mal brain activity, we performed LFP recordings in larval forebrain on 5 dpf scn1Labmor-
phants and control larvae (Fig 3A). Epileptiform paroxysmal events consisted of polyspiking
discharges with amplitudes equal to or exceeding threefold baseline (Fig 3C). Such recurrent
spontaneous epileptiform events occurred in 24/30 (80%) of scn1Labmorphants. Controls dis-
played baseline activity (Fig 3B and 3D1), whereas 2 out of 28 control larvae showed a single
epileptiform-like event (Fig 3C and 3D1). In seizure-positive larvae, the occurrence of poly-
spiking discharges was significantly higher in scn1Labmorphants, with a mean frequency of
12.5 events/10 min recording, in comparison to control larvae who only displayed one unique
epileptiform event (Fig 3D2). As a consequence, the cumulative duration of epileptiform
events, i.e. the fraction of time spent in epileptic activity was significantly higher in scn1Lab
morphants compared to control larvae (all larvae: Fig 3E1, seizure positive larvae: E2), whereas
the mean duration of epileptiform events was not affected (Fig 3F).
To confirm that the recorded brain activity are indeed synchronized neuronal discharges,
blockers of glutamate-mediated synaptic transmission were applied to scn1Labmorphants.
scn1Labmorphants were incubated with a mixture of 20 μM 6-cyano-7-nitroquinoxaline-
2,3-dione (CNQX), an AMPA/kainate receptor antagonist, and 50 μMDL-2-amino-5-phos-
phonopentanoic acid (APV), an NMDA receptor antagonist, 30 min prior to forebrain LFP re-
cordings [27]. Although application of CNQX/APV did not affect the occurrence of
polyspiking discharges (Fig 4A1), cumulative duration of events, Fig 4A2) and mean duration
of events Fig 4A3) were significantly reduced. These results show that recorded polyspiking
discharges are strongly inhibited by glutamate receptor blockers and thus dependent on synap-
tic activities. Therefore, it was concluded that recorded abnormal brain activity from scn1Lab
morphants is epileptiform.
As a positive control, seizures were induced in control larvae by addition of 20 mM pentyle-
netetrazole (PTZ), a commonly used chemoconvulsant, 30 min prior to midbrain LFP record-
ings [27]. Again the inhibitory effect of CNQX/APV application was tested. Blockers were
applied together with PTZ to control larvae, 30 min prior to midbrain LFP recordings. Applica-
tion of CNQX/APV significantly reduced occurrence of polyspiking discharges (Fig 4B1), cu-
mulative duration of events Fig 4B2) and mean duration of events (Fig 4B3).
Hyperthermia-induced abnormalities. Dravet syndrome frequently starts with convul-
sive seizures during the first year of life, which is triggered by elevated body temperature (due
for instance, to vaccination, infection or a hot bath) [1,29,30]. Oakley et al. also observed
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Fig 3. Spontaneous electrographic activity recorded from 5 dpf ATGMO- and CTRLMO-injected larvae. (A) Representative recording configuration of
an agar-immobilized zebrafish at 5 dpf. Note the recording electrode placed in the forebrain. (B) Extracellular recordings from the forebrain of 5 dpf CTRL-MO
larvae. (C) Representative epileptiform activities of 5 dpf ATGMO-injected larvae displaying polyspiking discharges. Top trace represents a typical
epileptiform pattern as seen in gap-free recordings. Bottom trace shows high-resolution magnification of epileptiform events mentioned above. (D)
Occurrence of epileptiform events in CTRL MO- and ATGMO-injected larvae. (D1) All larvae: CTRL MO 0.07±0.05 vs ATGMO 10.03±1.38 events/recording
(n = 28 and 30 larvae, respectively). (D2) Seizure-positive larvae: CTRLMO 1.0±0.0 vs ATGMO 12.54±1.27 events/recording (n = 2 and 24 larvae, 2 and
302 events analyzed, respectively). (E) Cumulative duration of epileptiform events in CTRL MO- and ATGMO-injected larvae. (E1) All larvae: CTRL MO 16.4
±12.3 vs ATGMO 4053±515 msec/10 min-recording (n = 28 and 30 larvae, respectively). (E2) Seizure-positive larvae: CTRL MO 290±91 vs ATGMO 5066
±441 events/recording (n = 2 and 24 larvae, respectively). (F) Mean duration of electrographic activity recorded from 5 dpf CTRL MO- and ATGMO-injected
larvae. ATGMO, 402.6±16.4 vs CTRLMO 230±91 msec (n = 302 and 2 events from 30 and 2 larvae, respectively, P = 0.3929). Statistical analysis was
performed using Student’s unpaired t-test or Mann–Whitney test for data that failed the normality test, as appropriate. Error bars on all graphs represent
standard error of mean (SEM). ** P 0.01, **** P0.0001.
doi:10.1371/journal.pone.0125898.g003
Fig 4. Inhibition of spontaneous or PTZ-induced electrographic discharges recorded from 5-dpf ATGMO- or CTRL MO-injected larvae after
application of CNQX/APV. (A1) Occurrence of polyspiking discharges recorded in ATGMO-injected larvae after 30 minutes treatment with 20 μMCNQX/
50 μMAPV in all larvae (CTRL MO, 1.0 ± 0 vs ATGMO, 12.5 ± 6.2 vs ATGMO+CNQX/APV 10.7 ± 5.5 events/10-min recording, n = 3, 24 and 7 larvae
respectively). (A2) Cumulative durations of polyspiking discharges recorded in ATGMO-injected larvae after 30 minutes treatment with 20 μMCNQX/50 μM
APV in all larvae (CTRLMO, 229.7 ±128.1 vs ATGMO, 5066 ± 2162 vs ATGMO+CNQX/APV 1749 ± 904.2 msec/10-min recording). (A3) Mean durations of
polyspiking discharges recorded in ATGMO-injected larvae after 30 minutes treatment with 20 μMCNQX/50 μMAPV in all larvae (CTRLMO, 229.7±128.1
vs ATGMO, 402.6 ± 285.3 vs ATGMO+CNQX/APV 163.3 ± 60.8 msec, n = 2, 302 and 75 events, respectively). (B1) Occurrence of polyspiking discharges
recorded in CTRL MO-injected larvae after 30 minutes treatment with 20 mM PTZ and 20 μMCNQX/50 μMAPV with 20 mM PTZ in all larvae (CTRLMO,
2.0 ± 2.0 vs CTRLMO+PTZ, 12.2 ± 4.6 vs CTRLMO+PTZ+CNQX/APV 2.7 ± 3.1 events/10-min recording, n = 3, 9 and 11 larvae respectively). (B2)
Cumulative durations of polyspiking discharges recorded in CTRL MO-injected larvae after 30 minutes treatment with 20 mM PTZ and 20 μMCNQX/50 μM
APV with 20 mM PTZ in all larvae (CTRLMO, 320.3 ± 279.7 vs CTRLMO+PTZ, 49640 ± 24833 vs CTRLMO+PTZ+CNQX/APV 7321 ± 9257 msec/10-min
recording). (B3) Mean duration of polyspiking discharges recorded in CTRLMO-injected larvae after 30 minutes treatment with 20 mM PTZ and 20 μM
CNQX/50 μMAPV with 20 mM PTZ in all larvae (CTRL MO, 117.2 ± 111.7 vs CTRLMO+PTZ, 4061 ± 1548 vs CTRLMO+PTZ+CNQX/APV 2301 ± 1810
msec, n = 3, 110 and 35 events, respectively). Statistical analysis was performed using Student’s unpaired t-test or Mann–Whitney test for data that failed the
normality test, as appropriate. Error bars on all graphs represent standard error of mean (SEM). ** P 0.01, **** P0.0001.
doi:10.1371/journal.pone.0125898.g004
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temperature-sensitive seizures in a mouse model of Dravet syndrome [20]. In line with these
findings, we investigated whether hyperthermia per se could influence larval behavior and
cause abnormalities and/or death in scn1Labmorphants by generating a rapid temperature
shift in the embryo medium from 28°C to 39°C, which was maintained for ten minutes. At
lower temperatures, heatshock-related abnormalities were not observed (data not shown).
To quantify the severity of hyperthermia-induced abnormalities, cumulative scoring was
used. Normal behavior was scored as 0, decreased touch response and partial loss of posture as
1, absent touch response and complete loss of posture as 2, and death as 3. To obtain a cumula-
tive score, the number of larvae was multiplied by the value that corresponded to the level of se-
verity, thus, the higher the value plotted, the more severe the observed phenotype was per
condition. We observed that scn1Labmorphants were extremely sensitive to heat shock com-
pared to control larvae between 5 and 7 dpf (Fig 5).
Seizures of DS typically do not begin before 5 months of age suggesting a strong correlation
between time of onset and brain development [1,20]. Moreover, it is also known that febrile sei-
zures are difficult to induce in rat pups due to the immaturity of the brain and immune system
[31,32]. Interestingly, we could detect a clear age-dependent transition for hyperthermia-in-
duced death in scn1Labmorphants as was also shown in a mouse model of Dravet syndrome
[20]. To be more specific, we could not detect a significant difference in hyperthermia-induced
abnormalities between scn1Labmorphants and control larvae before 5 dpf, while this was ap-
parent between 5 and 7 dpf.
Pharmacological evaluation of zebrafish Dravet morphant model
Commercially available AEDs known to modulate seizure progression of Dravet syndrome pa-
tients [33,34] were chosen to carry out a pharmacological evaluation of scn1Labmorphants.
We tested carbamazepine (CBZ), clobazam (CLB), stiripentol (STP), topiramate (TOP), sodi-
um valproate (VPA) and fenfluramine (FA) to evaluate their ability to rescue or worsen the
Fig 5. Confirmation of hyperthermia-induced abnormalities. The y-axis depicts the cumulative score to quantify the severity of hyperthermia-induced
abnormalities 24 hours after heatshock. Normal behavior was scored as 0, decreased touch response and partial loss of posture as 1, absent touch response
and complete loss of posture as 2, and death as 3. The number of larvae was multiplied by the value corresponding to the level of severity. The x-axis
corresponds to CTRL MO- and ATGMO-injected larvae from 3 dpf to 7 dpf (day of heatshock). Data of graphs are pooled together from three independent
experiments with 8 larvae per condition. Statistical analysis was performed using two-way ANOVA with Bonferroni post-tests. Error bars on all graphs
represent standard error of mean (SEM). * P 0.05, ** P 0.01, *** P0.001.
doi:10.1371/journal.pone.0125898.g005
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abnormal larval hyperactivity of scn1Labmorphants to determine whether the tested AEDs
would ameliorate or worsen the Dravet morphant phenotype.
Assessment of larval locomotor response to AEDs. The locomotor behavior of scn1Lab
morphants in response to different AEDs was investigated using the ZebraBox system between
4 and 5 dpf, since they displayed significantly higher total movement compared to control larvae
(Fig 1C). Therefore, all the pharmacological experiments were carried out during this develop-
mental period to observe the highest difference. With the replenishment of AEDs after 24 hours
we wanted to investigate a more chronic effect of the drugs as opposed to acute exposure. The
maximum tolerated concentration (MTC) of drugs was determined and used as the highest con-
centration. We tested CBZ (MTC: 50 μM), which would typically aggravate seizures, and is thus
contraindicated in the treatment of Dravet syndrome [33]. CBZ had either no significant effect
or induced a slight increase in the activity of scn1Labmorphants (Fig 6A1 and 6A2). Then, CLB
Fig 6. Effect of carbamazepine (CBZ), clobazam (CLB), stiripentol (STP), topiramate (TOP), sodium valproate (VPA) and fenfluramine (FA) on total
larval locomotor movement of 4 and 5 dpf CTRLMO- and ATGMO-injected larvae. (A1, B1, C1, D1, E1, F1) 4 dpf CTRL MO- and ATGMO-injected
larvae after 24 hours of incubation of vehicle (VHC) and CBZ, CLB, STP, TOP, VPA or FA, respectively. (A2, B2, C2, D2, E2, F2) 5 dpf CTRL MO- and ATG
MO-injected larvae after 48 hours of incubation of vehicle (VHC) and CBZ, CLB, STP, TOP, VPA or FA, respectively. Total movement is expressed in
“actinteg” units over 1 hour of tracking experiment (30-min intervals). Data were pooled from three independent experiments with twelve larvae per injection
condition. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Dunnett’s test for multiple comparisons. Error bars on
all graphs represent standard error of mean (SEM). * P 0.05, ** P 0.01, *** P0.001, **** P0.0001.
doi:10.1371/journal.pone.0125898.g006
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(MTC: 150 μM), STP (MTC: 12.5 μM) and TOP (MTC: 200 μM) were tested as they are sup-
posed to ameliorate the seizures [33,34]. It was found that CLB significantly decreased the hy-
peractivity of scn1Labmorphants even after 24 hours of incubation at 4 dpf. Moreover, its effect
persisted until 5 dpf (Fig 6B1 and 6B2. Similarly, STP could significantly suppress the hyperac-
tivity of scn1Labmorphants after 48-hour incubation at 5 dpf (Fig 6C1 and 6C2). TOP de-
creased the hyperactivity of scn1Labmorphants at 4 and 5 dpf (Fig 6D1 and 6D2). We found
that VPA (MTC: 100 μM) could also significantly decrease the total movement of scn1Labmor-
phants at 4 and 5 dpf (Fig 6E1 and 6E2). Finally, we also tested FA (MTC: 50 μM) and observed
significantly decreased locomotor activity of scn1Labmorphants at 4 and 5 dpf, (Fig 6F1 and
6F2).
Forebrain local field potential recordings. Two of the above-mentioned AEDs were se-
lected for forebrain local field potential recordings, namely fenfluramine (FA), as a promising
drug candidate for DS, and sodium valproate (VPA) as a positive control, given the latter has
previously been shown to suppress seizures in the scn1Lab/didymutant [21].
The effect of fenfluramine on the occurrence of seizures was then examined in 5-dpf
scn1Labmorphants and control larvae. Application of vehicle was used as a negative control.
None of the control larvae displayed any epileptiform activity after incubation with vehicle,
50 μM fenfluramine or 100 μM sodium valproate (Figs 7A and 6C1–6C3). Moreover, applica-
tion of vehicle had no effect on the frequency (data not shown in Fig 7), cumulative duration
and mean duration of events in ATGMO-injected larvae (data not shown in Fig 7).
Application of fenfluramine or sodium valproate induced a dramatic decrease in the occur-
rence of epileptic events. Indeed, incubation of scn1Labmorphants with vehicle induced epi-
leptiform events in 10 out of 12 larvae (Fig 7B) whereas only 1 out of 30 displayed such
epileptiform pattern following application of fenfluramine or sodium valproate. The occur-
rence of polyspiking discharges was significantly decreased after treatment with 50 μM fenflur-
amine or 100 μM sodium valproate, compared to VHC (Fig 7C1). The cumulative duration of
events was significantly decreased as well whereas the mean duration of events was not affected
in seizure-positive larvae (Fig 7C2 and 7C3).
Hyperthermia-induced abnormalities. The potential of fenfluramine and sodium valpro-
ate to reduce hyperthermia-induced abnormalities was investigated on 5-dpf scn1Labmor-
phants and control larvae after 24 hours of treatment in comparison to vehicle. Surprisingly,
treatment with both fenfluramine and sodium valproate slightly, but non-significantly reduced
hyperthermia-induced abnormalities (Fig 8), thereby suggesting that the mechanisms causing
these abnormalities are at least in part unrelated to the seizure background that can be rescued
by fenfluramine and sodium valproate.
In general, hyperthermia and/or fever are known to induce molecular, structural and func-
tional changes, including increased expression of immune mediators (IL1-β, IL-6, neuropep-
tide Y), altered ion channel kinetics and axonal conduction velocity, and over-activation of
TRPV4-channels. These changes render the normal network hyperexcitable and are associated
with febrile seizures [35–37]. It is currently not clear which of these mechanisms are involved
in the hyperthermia-induced abnormalities specifically seen in scn1Labmorphants under high,
non-physiological temperatures. Further analysis will therefore be needed to improve our un-
derstanding of the lack of activity of these two drugs under these conditions.
Conclusion
In this study, we generated a zebrafish model of Dravet syndrome through the antisense-medi-
ated morpholino knockdown of the zebrafish scn1Lab gene. We show that scn1Labmorphants
display hyperactivity, abnormal myoclonic-like behavior and epileptiform brain activity.
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Fig 7. Effect of fenfluramine and sodium valproate on polyspiking discharges recorded from 5 dpf-ATGMO- and CTRLMO-injected larvae. (A)
Representative electrographic activities recorded in CTRL MO larvae incubated with vehicle (VHC), 50 μM fenfluramine (FA) or 100 μM sodium valproate
(VPA). (B) Representative electrographic activities recorded in ATGMO-injected larvae incubated with the same compounds. (C1) Occurrence of polyspiking
discharges recorded in ATGMO-injected larvae after treatment with VHC, 50 μM FA and 100 μMVPA in all larvae. (C2) Cumulative durations of polyspiking
discharges recorded in ATGMO-injected larvae after treatment with VHC, 50 μM FA and 100 μMVPA in all larvae. (ATGMO + FA: 0.2±0.2 events and 88±88
msec/10-min recording; ATGMO + VPA: 0.7±0.7 events and 165±165 msec/10-min recording, n = 20 and 10 larvae, respectively) compared to VHC-treated
larvae (ATGMO + VHC: 9.16±2.36 events and 3533±1113 msec/10-min recording; n = 12 larvae; (C3) Mean durations of polyspiking discharges recorded in
ATGMO-injected larvae after treatment with VHC, 50 μM FA and 100 μMVPA in seizure-positive larvae (ATGMO + VHC: 385.4±34.1 msec; ATGMO + FA:
439.9±33.2 msec; ATGMO + VPA: 235.7±33.2 msec; n = 110, 4 and 7 events analyzed, respectively). Statistical analysis was performed using Student’s
unpaired t-test or Mann–Whitney test for data that failed the normality test, as appropriate. Error bars on all graphs represent standard error of mean (SEM).
*** P0.001, **** P0.0001.
doi:10.1371/journal.pone.0125898.g007
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Furthermore, it was also shown that these larvae are remarkably sensitive to hyperthermia.
Pharmacological evaluation revealed that clobazam, stiripentol, topiramate, sodium valproate
and fenfluramine significantly decreased the hyperactivity of scn1Labmorphants, while carba-
mazepine, a contra-indicated drug for the treatment of Dravet, had no effect. Moreover, sodi-
um valproate and fenfluramine significantly reduced epileptiform discharges in scn1Lab
morphants. Furthermore, the Dravet morphant phenotype is remarkably comparable to that of
scn1Labmutants with no additional dysmorphologies, and normal control MO knockdown
larvae, suggesting that the effects of the ATGMO are highly specific. Altogether, we are able to
phenocopy the scn1Labmutant, which is generally accepted as the major criterion for demon-
strating knockdown specificity [38].
The scn1Labmorphants described here have certain advantages as a zebrafish model of Dra-
vet syndrome in comparison to scn1Labmutants. One advantage is that there is no need to
breed mutants over several generations to obtain homozygosity, and no need to genotype all
larvae in order to identify homozygotes. In addition, scn1Labmorphants show high penetrance
(>80%), enabling experiments to be performed on nearly all knockdown larvae at early devel-
opmental stages (i.e. prior to the hyperpigmentation phenotype observed from 3 dpf onwards).
This contrasts with the 4-fold lower number of embryos with a Dravet-like phenotype for
scn1Labmutants, as heterozygous crosses produce only 25% homozygous recessive mutants
per mating. Moreover, it is possible to introduce morpholinos into various transgenic reporter
Fig 8. Effect of fenfluramine and sodium valproate on hyperthermia-induced abnormalities on 5 dpf-ATGMO- and CTRLMO-injected larvae. The y-
axis depicts the cumulative score to quantify the severity of hyperthermia-induced abnormalities 24 hours after heatshock. Normal behavior was scored as 0,
decreased touch response and partial loss of posture as 1, absent touch response and complete loss of posture as 2, and death as 3. The number of larvae
was multiplied by the value corresponding to the level of severity. The x-axis corresponds to CTRL MO- and ATGMO-injected larvae at 5 dpf (day of
heatshock). 4-dpf scn1Labmorphants and control larvae were exposed to the compounds 24 hours prior to heatshock treatment. Data of graphs are pooled
together from three independent experiments with 8 larvae per condition. Statistical analysis was performed using two-way ANOVA with Bonferroni post-
tests. Error bars on all graphs represent the standard error of mean (SEM). ** P 0.01.
doi:10.1371/journal.pone.0125898.g008
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lines to easily and rapidly investigate the behavioral, cellular and molecular aspects of Dravet
syndrome further.
To our knowledge, this is the first study demonstrating effective seizure inhibition of fen-
fluramine in an animal model of Dravet syndrome. The high efficacy of fenfluramine in reduc-
ing convulsions and epileptiform activity in scn1Lab knockdown zebrafish larvae demonstrates
their utility as an animal model of Dravet syndrome. This novel zebrafish Dravet model will be
useful in identifying and elucidating novel mechanisms of action of potentially therapeutic
small molecules, for drug repurposing screens, and for disentangling the mechanisms underly-
ing cardiotoxicity and the anticonvulsant activity of fenfluramine. Thereby we underscore the
validity of our model as a rapid first-pass screening tool in assessing the anticonvulsant activity
of novel analogs with improved activity and significantly milder or no side effects that can po-
tentially be used therapeutically in Dravet syndrome children.
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